Processa Pharma rises as cancer treatment shows promise in early-stage study
25/01/2024 14:20
** Shares of drug developer Processa Pharmaceuticals
PCSA.O rise 64.4% to $3.35 premarket
** Co says four of five patients that completed an efficacy
analysis during an early-stage study of its experimental cancer
treatment Next Generation Capecitabine, in gastrointestinal
cancer, showed a positive response
** The treatment that is a combination of PCSA's cancer
therapy candidate PCS6422 and Roche's approved chemotherapy drug
capecitabine showed drug levels achieved in patients' bodies
that were 2-10 times higher than capecitabine alone
** The mid-stage trial of the treatment will be in types of
breast cancer on co's agreement with the U.S. FDA that the
early-stage data can be used to support the study
** Up to Wednesday's close, stock down 90% in the last 12
months
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))